Interferon gamma-1b
Actimmune (interferon gamma-1b) is a protein pharmaceutical. Interferon gamma-1b was first approved as Actimmune on 1999-02-25. It is used to treat bacterial infections, brain neoplasms, chronic hepatitis c, colorectal neoplasms, and cryoglobulinemia amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Show 2 more
Trade Name
FDA
EMA
Actimmune
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Interferon gamma-1b
Tradename | Proper name | Company | Number | Date | Products |
|---|---|---|---|---|---|
| Actimmune | interferon gamma-1b | Horizon Therapeutics Public | N-103836 RX | 1999-02-25 | 1 products |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| actimmune | Biologic Licensing Application | 2021-05-07 |
Indications
FDA
EMA
Show 14 more
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
interferon gamma-1b, Actimmune, Horizon Therapeutics Ireland DAC | |||
| 2107-02-10 | Orphan excl. | ||
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
449 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 5 | 7 | 2 | 5 | 50 | 67 |
| Infections | D007239 | EFO_0000544 | — | 9 | 12 | 3 | 2 | 25 | 45 |
| Hepatitis | D006505 | — | K75.9 | 6 | 12 | 5 | 5 | 9 | 32 |
| Communicable diseases | D003141 | — | — | 7 | 9 | 1 | 1 | 17 | 31 |
| Latent tuberculosis | D055985 | — | Z22.7 | — | — | 2 | 5 | 24 | 31 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 3 | 8 | 5 | 4 | 7 | 25 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 7 | 9 | — | 3 | 7 | 24 |
| Hepatitis c | D006526 | — | B19.2 | 4 | 9 | 2 | 1 | 7 | 19 |
| Covid-19 | D000086382 | — | U07.1 | 1 | 1 | 1 | 1 | 13 | 17 |
| Chronic hepatitis | D006521 | — | K73.9 | 2 | 4 | 2 | 4 | 6 | 17 |
Show 20 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Melanoma | D008545 | — | — | 28 | 15 | 3 | — | — | 37 |
| Carcinoma | D002277 | — | C80.0 | 19 | 17 | 1 | — | — | 28 |
| Neoplasms | D009369 | — | C80 | 14 | 8 | 2 | — | 3 | 23 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 13 | 10 | 2 | — | 1 | 19 |
| Lymphoma | D008223 | — | C85.9 | 6 | 6 | 2 | — | 1 | 12 |
| Fibrosis | D005355 | — | — | 3 | 5 | 4 | — | 1 | 11 |
| Pneumonia | D011014 | EFO_0003106 | J18 | 1 | 2 | 2 | — | 5 | 10 |
| Skin neoplasms | D012878 | EFO_0004198 | C44 | 4 | 5 | 2 | — | — | 10 |
| Recurrence | D012008 | — | — | 5 | 4 | 2 | — | 1 | 9 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | — | 3 | 1 | — | 5 | 9 |
Show 34 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Syndrome | D013577 | — | — | 3 | 5 | — | — | 4 | 12 |
| Non-small-cell lung carcinoma | D002289 | — | — | 11 | 7 | — | — | — | 12 |
| Sarcoma | D012509 | — | — | 6 | 4 | — | — | — | 10 |
| Leukemia | D007938 | — | C95 | 7 | 3 | — | — | 1 | 10 |
| Colorectal neoplasms | D015179 | — | — | 5 | 6 | — | — | — | 10 |
| Mycobacterium infections | D009164 | — | A31.9 | 2 | 2 | — | — | 5 | 9 |
| Pancreatic neoplasms | D010190 | EFO_0003860 | C25 | 7 | 3 | — | — | — | 9 |
| Lung neoplasms | D008175 | — | C34.90 | 7 | 5 | — | — | — | 9 |
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | 2 | 3 | — | — | 5 | 8 |
| Squamous cell carcinoma | D002294 | — | — | 6 | 4 | — | — | — | 8 |
Show 124 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | 2 | — | — | — | 3 | 5 |
| Virus diseases | D014777 | — | B34 | 1 | — | — | — | 4 | 5 |
| Asthma | D001249 | EFO_0000270 | J45 | 1 | — | — | — | 3 | 4 |
| Merkel cell carcinoma | D015266 | EFO_1001471 | C4A | 3 | — | — | — | — | 3 |
| Hematopoietic stem cell transplantation | D018380 | — | — | 2 | — | — | — | 1 | 3 |
| Rheumatic diseases | D012216 | — | M79.0 | 1 | — | — | — | 1 | 2 |
| Collagen diseases | D003095 | — | — | 1 | — | — | — | 1 | 2 |
| Osteosarcoma | D012516 | — | — | 2 | — | — | — | — | 2 |
| Herpes zoster | D006562 | EFO_0006510 | B02 | 1 | — | — | — | 1 | 2 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | 1 | — | — | — | 1 | 2 |
Show 44 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney transplantation | D016030 | — | — | — | — | — | — | 6 | 6 |
| Respiratory tract infections | D012141 | — | J06.9 | — | — | — | — | 5 | 5 |
| Hemorrhage | D006470 | MP_0001914 | R58 | — | — | — | — | 2 | 2 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | — | 2 | 2 |
| Pulmonary arterial hypertension | D000081029 | — | — | — | — | — | — | 2 | 2 |
| Autonomic nervous system diseases | D001342 | EFO_0009532 | G90 | — | — | — | — | 2 | 2 |
| Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | — | 2 | 2 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | — | — | — | — | 2 | 2 |
| Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | — | — | — | 2 | 2 |
| Mycobacterium tuberculosis | D009169 | NCBITaxon_1773 | — | — | — | — | — | 2 | 2 |
Show 103 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Interferon gamma-1b |
| INN | — |
| Description | Actimmune, Betaferon, Extavia (interferon gamma-1b) is a protein pharmaceutical. Interferon gamma-1b was first approved as Actimmune on 1995-11-30. It is used to treat bacterial infections, brain neoplasms, chronic hepatitis c, colorectal neoplasms, and cryoglobulinemia amongst others in the USA. It has been approved in Europe to treat multiple sclerosis. |
| Classification | Protein |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
| PDB | — |
| CAS-ID | — |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201564 |
| ChEBI ID | — |
| PubChem CID | — |
| DrugBank | DB00033 |
| UNII ID | — |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Actimmune – Horizon Therapeutics Public
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Actimmune – Intermune
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 267,923 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,817 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use